Home > Insider Trading > Filing (0001209191-16-151526)

Filing Details

Accession Number:: 0001209191-16-151526
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2016-11-21 21:10:30
Reporting Period:: 2016-11-17

Filing Date:: 2016-11-21
Accepted Time:: 2016-11-21 21:10:30
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1088856	Corcept Therapeutics Inc	CORT	Pharmaceutical Preparations (2834)	770487658

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1419701	L.p. Partners Venture Longitude	C/O Longitude Capital Partners, Llc 800 El Camino Real, Suite 220 Menlo Park CA 94025	No	No	Yes	No
1430719	Longitude Capital Associates, L.p.	800 El Camino Real Suite 220 Menlo Park CA 94024	No	No	Yes	No
1430720	Longitude Capital Partners, Llc	800 El Camino Real Suite 220 Menlo Park CA 94024	No	No	Yes	No
1431159	Juliet Bakker Tammenoms	800 El Camino Real Suite 220 Menlo Park CA 94024	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2016-11-17	318,764	$9.64	14,026,757	No	4	S	Direct
Common Stock	Disposition	2016-11-17	6,389	$9.64	185,133	No	5	S	Indirect	By LCA
Common Stock	Disposition	2016-11-18	98,586	$9.47	13,928,171	No	4	S	Direct
Common Stock	Disposition	2016-11-18	1,976	$9.47	183,157	No	4	S	Indirect	By LCA
Common Stock	Disposition	2016-11-21	116,058	$9.39	13,812,113	No	4	S	Direct
Common Stock	Disposition	2016-11-21	2,327	$9.39	180,830	No	4	S	Indirect	By LCA

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct
No	5	S	Indirect	By LCA
No	4	S	Direct
No	4	S	Indirect	By LCA
No	4	S	Direct
No	4	S	Indirect	By LCA

Footnotes

Reflects sales of common stock executed in multiple transactions at prices ranging from $9.5300 to $9.8000. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Corcept Therapeutics Incorporated or a security holder of Corcept Therapeutics Incorporated full information regarding the number of shares and prices at which the sales were effected.
Reflects transactions and holdings of shares of common stock of the Issuer held of record by Longitude Venture Partners, L.P. ("LVP"). This report is filed jointly by LVP, Longitude Capital Partners, LLC ("Longitude Capital"), the sole general partner of LVP, and Juliet Tammenoms Bakker, a managing member of Longitude Capital, with respect to the securities held and transactions effected by LVP. LVP may also be deemed a director by virtue of its right to nominate a representative to serve on the Issuer's Board of Directors. Patrick G. Enright currently serves as LVP's representative on the Issuer's Board of Directors and files separate reports under Section 16(a) of the Securities Exchange Act of 1934 to report transactions in securities of the Issuer. Each of Longitude Capital and Ms. Bakker disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interest therein.
Reflects transactions and holdings of shares of common stock of the Issuer held of record by Longitude Capital Associates, L.P. ("LCA"). This report is jointly filed by LCA, Longitude Capital, the sole general partner of LCA, and Ms. Bakker, a managing member of Longitude Capital, with respect to the securities held and transactions effected by LCA. Each of Longitude Capital and Ms. Bakker disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interest therein.
Reflects sales of common stock executed in multiple transactions at prices ranging from $9.4500 to $9.5400. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Corcept Therapeutics Incorporated or a security holder of Corcept Therapeutics Incorporated full information regarding the number of shares and prices at which the sales were effected.
Reflects sales of common stock executed in multiple transactions at prices ranging from $9.3300 to $9.4800. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Corcept Therapeutics Incorporated or a security holder of Corcept Therapeutics Incorporated full information regarding the number of shares and prices at which the sales were effected.